Collecting past footprint towa

Professor Shi yuankai Tribune: can you talk about this year's keynote report set to be an international forum designed it?stone Professor: Medical Oncology today, only half a century of history. After entering the 21st century, medical oncology treatment from conventional cytotoxic drugs as the principal of the treatment, into cytotoxic drugs as the basis, targeting drug growing more and more important position, we enter the patients genetic background and molecular expression products, to &ldquo it; the difference ” treatment times. In this context, medical oncology physicians how to grasp and meet the development trend of the times? Chinese doctors are concerned, because of differences in race and genetic background, we have created more and more to explore this opportunity of national characteristics and modes of therapy in patients with cancer, how are we going to play their role?in view of this, this year's annual meeting in “ past, present and future of medical oncology ” as the theme, has set up a special forum, this is the only theme of a conference report, in my opinion, this concert for all medical oncology doctor, even medical workers is of great significance in the field.at the same time, this year is the Conference of medical oncology (CSMO) 5th year, is also in honour of the past 5 years, we had such a forum, invited from the United States, Europe and Japan's top experts, and our adhering and Guan Zhong-Zhen: Professor, academician, speaking for different themes, looking back and looking forward to the future. It turns out that we have also listened to a really good and successful academic reports.Tribune: in processes of individual treatment of cancer, cancer doctors in China face what challenges?Shi yuankai Professor: I think that is mainly in the areas of clinical research and study on transformation of. Only to raise the level of clinical research, strengthened, deeper into the transformational research done will it be possible to get more experience, get more data for our own patients, more outcomes for our patients to share.at present, the main research results have come from Europe, the United States and Japan. Over the years, Chinese scholars ' research began in an important international meeting, but I think the number is too small. Now,   national on this aspects given has great concern, in “863” plans, and “ Eleven-Five ” and “ Twelve-Five ” major new drug creation, and major technology special, related project in the,   inputs has quite more of funding,   encourages China Medical territories of people with lofty ideals were to established a full of including clinical Qian research and clinical research zainei of new drug research and development system. This will enhance the research ability,   speed up research and raise the level of study. This is one aspect of Chinese doctors should be able to do.on the other hand is how to regulate the treatment of behaviour? Individualized treatment is not under treatment, should individual treatment based on strict clinical treatment. First principles, then to talk about the individual, both. In my opinion, these two aspects is that we should continue to strengthen, this calls for our entire industry practitioners constantly improve their knowledge, improve their knowledge structure, track the latest development of international, doing so can keep pace with the times, always stand in the forefront of the times. The main purpose of this is our CSMO —— Exchange results, solidifying consensus, update knowledge.Tribune: compared with previous years, the current session of the General Assembly what are the characteristics?Professor Shi yuankai: through the past 4 years of development, China Medical Oncology fellow us such a meeting has been widely recognized as one of the medical oncology in China scholars Exchange platform, it not only looks forward to the field of Chinese medical oncology fellow, also becomes committed to transforming research, basic research and drug develo